2023
Early treatment of neonatal diabetes with oral glibenclamide in an extremely preterm infant
Galderisi A, Kermorvant‐Duchemin E, Daruich A, Bonnard A, Lapillonne A, Aubelle M, Perrella B, Vial Y, Cave H, Berdugo M, Jarreau P, Polak M, Beltrand J. Early treatment of neonatal diabetes with oral glibenclamide in an extremely preterm infant. 2023, 64: 161-166. PMID: 36873092, PMCID: PMC9981413, DOI: 10.1002/jmd2.12358.Peer-Reviewed Original ResearchEarly treatmentNeonatal diabetesPreterm babiesPreterm infantsGlucose profilesComplete retinal vascularizationLow glucose intakeBlood glucose testMonth of birthOral glibenclamideGlycemic controlMonth 6Gestational ageNasogastric tubeRetinal vascularizationMaternal milkGlucose intakeInsulin treatmentKCNJ11 genesGlucose testHyperglycemic episodesSpecific treatmentProgressive regressionDiabetesHomozygous variant
2019
A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes.
Galderisi A, Sherr JL. A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes. Pediatric Annals 2019, 48: e311-e318. PMID: 31426099, DOI: 10.3928/19382359-20190725-03.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsContinuous glucose monitoringType 1 diabetesGlycemic controlContinuous subcutaneous insulin infusion pumpClosed-loop insulin deliveryIntensive insulin treatmentMultiple daily injectionsChronic medical conditionsLoop insulin deliveryPediatric clinical practiceInsulin infusion pumpDaily injectionsBlood glucoseInsulin treatmentMedical conditionsDiabetes treatmentClinical practiceNew treatmentsGlucose monitoringInfusion pumpInsulin deliveryT1DDiabetesTreatmentSuspension device